Objective: To detect the expression of L-type amino acid transporter 1 (LAT1) in non-Hodgkin's lymphoma (NHL) tissues, and analyze its effect on clinicopathological characteristics and prognosis of patients.
Methods: A total of 92 NHL patients who were treated in our hospital from January 2017 to April 2019 were collected. The expression of LAT1 in NHL tissue was detected by immunohistochemistry and compared between patients with different pathological features (including sex, Ann Arbor stage, extranodal infiltration, Ki-67). The risk factors affecting mortality were analyzed using univariate and multivariate Cox proportional hazards regression. Receiver operating characteristic (ROC) curve was used to detect the predictive value of percentage of LAT1-positive cells in NHL tissue for patient mortality, and analyzing the effect of percentage of LAT1-positive cells on survival rate.
Results: LAT1 was positively expressed in NHL tissue. The high expression rate of LAT1 in Ann Arbor stage III and IV groups were higher than that in Ann Arbor stage I group, that in extranodal infiltration group was higher than non-extranodal infiltration group, and that in Ki-67 positive expression group was higher than Ki-67 negative expression group (all P < 0.05). The remission rate after 3 courses of treatment in high-LAT1 expression group was 70.7%, which was lower than 91.2% in low-LAT1 expression group (P < 0.05). Ann Arbor stage III and IV, extranodal invasion, Ki-67 positive expression and increased expression of LAT1 (LAT1-positive cell percentage score ≥2) were risk factors for mortality. The cut-off value of percentage of LAT1-positive cells for predicting NHL death was 45.6%, and the area under the ROC curve was 0.905 (95%CI: 0.897-0.924). The 3-year survival rate of high-LAT1 level group (the percentage of LAT1-positive cells≥45.6%) was 50.00%, which was lower than 78.26% of low-LAT1 level group (P < 0.05).
Conclusion: The expression level of LAT1 in NHL tissue increases, which affects Ann Arbor stage and extranodal infiltration of patients. LAT1 is a risk factor for death.
题目: L型氨基酸转运蛋白1的表达对非霍奇金淋巴瘤临床病理特征和预后的影响.
目的: 检测非霍奇金淋巴瘤（NHL）组织中L型氨基酸转运蛋白1（LAT1）的表达，分析LAT1对患者临床病理特征和预后的影响。.
方法: 收集2017年1月至2019年4月在本院接受治疗的NHL患者92例，免疫组织化学检测NHL组织中LAT1的表达，比较不同病理特征（包括性别、Ann Arbor分期、结外浸润、Ki-67）患者组间LAT1的表达差异，单因素和多因素Cox回归分析影响患者死亡的危险因素，受试者工作曲线（ROC）检测NHL组织中LAT1阳性细胞百分比对患者死亡的预测价值，分析LAT1阳性细胞百分比对患者生存率的影响。.
结果: LAT1在NHL组织中呈阳性表达，Ann Arbor分期III期和IV期组LAT1高表达率高于I期组，结外浸润组LAT1高表达率高于无结外浸润组，Ki-67阳性表达组LAT1高表达率高于阴性表达组，比较差异均有统计学意义（均P <0.05）。LAT1高表达组治疗3个疗程后的缓解率为70.7%，低于低表达组的91.2%，比较差异有统计学意义（P <0.05）。Ann Arbor分期III期、IV期、结外浸润、Ki-67阳性表达和LAT1表达增加（即LAT1阳性细胞比例评分≥2）为患者死亡的危险因素。LAT1阳性细胞百分比预测NHL死亡的截断值为45.6%，曲线下面积为0.905（95%CI: 0.897-0.924）。LAT1高水平组（LAT1阳性细胞百分比≥45.6%）3年生存率为50.00%，低于LAT1低水平组的78.26%（P <0.05）。.
结论: LAT1在NHL组织中表达水平增加，影响患者的肿瘤分期和结外浸润，是患者死亡的危险因素。.
Keywords: L-type amino acid transporter 1; non Hodgkin′s lymphoma; survival rate.